AbCellera (Vancouver)

disponible en anglais

AbCellera and Eli Lilly and Company recently announced they have entered into an agreement to co-develop antibody products for the treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The collaboration will leverage AbCellera’s rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) Program, and Lilly’s global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies.

The Government of Canada has announced funding for AbCellera, a Vancouver-based was the first company in North America to receive a sample from a convalescent patient, and within days identified over 500 human antibodies that are candidates for development as a treatment.

Learn More